You may qualify for Libre systems if you have been diagnosed with T1D or T2D, meet with your healthcare provider every 6 months, and one of the following applies:
Your doctor recommends daily insulin to help control your glucose.
You have a history of problematic hypoglycemia (or low sugar levels).
T1D = type 1 diabetes; T2D = type 2 diabetes
You (or members of your family) may qualify for Libre systems if you have been diagnosed with T1D or T2D, have filled an insulin prescription in the last 6 months, and one of the following applies:
You (or your family member) are currently being treated with insulin.
You (or your family member) are receiving subcutaneous insulin infusion (i.e. insulin pump).
You (or your family member) are receiving insulin therapy, and there is a history of medical treatment for severe hypoglycemia (or low sugar levels).
Prior authorization (PA) with VA or TRICARE
To qualify for coverage you may need PA from your insurance plan.
CGM = continuous glucose monitor(ing)
To learn more about pharmacy costs, visit the TRICARE Pharmacy Program.
Start the conversation with your healthcare provider.
To see if Libre systems are right for you, use our discussion guide to help start the conversation.
Get your prescription.
During your conversation with your healthcare provider, ask for a prescription for one of our Libre CGM systems.
Fill your prescription.
Fill your prescription for one of our Libre CGM systems at a pharmacy* that accepts VA and TRICARE customers.
Yes. You can pay out-of-pocket for Libre systems if they aren’t covered by your VA/TRICARE plan.
Please contact your pharmacy* or supplier* for more information.
Abbott provides this information as a courtesy and does not guarantee payment or coverage.
* Participating pharmacies and durable medical equipment (DME) suppliers are subject to change without notice. Product availability may vary by retailer.
The Libre systems are covered by the Department of Defense TRICARE for those who qualify3,4. Please contact your healthcare provider—they will need to provide PA.
References: 3. Department of Defense Pharmacy and Therapeutics Committee. “Recommendations from the February 2024 Meeting.” U.S. Department of Defense. Accessed October 27, 2025. https://health.mil/Reference-Center/Meeting-References/2024/03/27/UF-BAP-Background-Document-April-3-2024-time-zone-edited. 4. Department of Defense Pharmacy and Therapeutics Committee. “Recommendations from the November 2022 Meeting.” U.S. Department of Defense. Accessed October 27, 2025. https://www.health.mil/Reference-Center/Meeting-References/2022/12/16/BAP-Background-Document-for-the-Nov-2022-PT-Meeting.
In order to qualify for coverage, your healthcare provider will need to confirm2:
Reference: 2. Memorandum, Updated Guidance on Patient Selection Criteria for Continuous Glucose Monitors (CGM), July 7, 2023. Department of Veterans Affairs.
In order to qualify for coverage, your healthcare provider will need to confirm3,4:
References: 3. Department of Defense Pharmacy and Therapeutics Committee. “Recommendations from the February 2024 Meeting.” U.S. Department of Defense. Accessed October 27, 2025. https://health.mil/Reference-Center/Meeting-References/2024/03/27/UF-BAP-Background-Document-April-3-2024-time-zone-edited. 4. Department of Defense Pharmacy and Therapeutics Committee. “Recommendations from the November 2022 Meeting.” U.S. Department of Defense. Accessed October 27, 2025. https://www.health.mil/Reference-Center/Meeting-References/2022/12/16/BAP-Background-Document-for-the-Nov-2022-PT-Meeting.
FreeStyle Libre 3 system is cleared to be used by children 4 years and older with Libre 3 sensor and 2 years and older with Libre 3 Plus sensor.
FreeStyle Libre 2 system is cleared to be used by children 4 years and older with Libre 2 sensor and 2 years and older with Libre 2 Plus sensor.
Medicare and other payor criteria may apply.
Abbott provides this information as a courtesy and does not guarantee payment or coverage.
* Participating pharmacies and durable medical equipment (DME) suppliers are subject to change without notice. Product availability may vary by retailer.
References: 1. Data on file. Abbott Diabetes Care, Inc. 2. Memorandum, Updated Guidance on Patient Selection Criteria for Continuous Glucose Monitors (CGM), July 7, 2023. Department of Veterans Affairs. 3. Department of Defense Pharmacy and Therapeutics Committee. “Recommendations from the February 2024 Meeting.” U.S. Department of Defense. Accessed October 27, 2025. https://health.mil/Reference-Center/Meeting-References/2024/03/27/UF-BAP-Background-Document-April-3-2024-time-zone-edited. 4. Department of Defense Pharmacy and Therapeutics Committee. “Recommendations from the November 2022 Meeting.” U.S. Department of Defense. Accessed October 27, 2025. https://www.health.mil/Reference-Center/Meeting-References/2022/12/16/BAP-Background-Document-for-the-Nov-2022-PT-Meeting.
ADC-37052 v7.0
The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.
Do you wish to leave this site?
